دورية أكاديمية
Clinical Assessment of Risk Factors for Renal Atrophy After Percutaneous Nephrolithotomy.
| العنوان: | Clinical Assessment of Risk Factors for Renal Atrophy After Percutaneous Nephrolithotomy. |
|---|---|
| المؤلفون: | Xiangrui Y; Department of Urology, Traditional Chinese Medicine Hospital, Chongqing, China (mainland)., Xiong W; Department of Urology, Traditional Chinese Medicine Hospital, Chongqing, China (mainland)., Xi W; Department of Urology, Traditional Chinese Medicine Hospital, Chongqing, China (mainland)., Yuanbing J; Department of Urology, Traditional Chinese Medicine Hospital, Chongqing, China (mainland)., Shenqiang Q; Department of Urology, Traditional Chinese Medicine Hospital, Chongqing, China (mainland)., Yu G; Department of Urology, Traditional Chinese Medicine Hospital, Chongqing, China (mainland). |
| المصدر: | Medical science monitor : international medical journal of experimental and clinical research [Med Sci Monit] 2020 Sep 28; Vol. 26, pp. e919970. Date of Electronic Publication: 2020 Sep 28. |
| نوع المنشور: | Clinical Trial; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: International Scientific Information, Inc Country of Publication: United States NLM ID: 9609063 Publication Model: Electronic Cited Medium: Internet ISSN: 1643-3750 (Electronic) Linking ISSN: 12341010 NLM ISO Abbreviation: Med Sci Monit Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2014- : Smithtown, NY : International Scientific Information, Inc. Original Publication: Warsaw, Poland : Medical Science International |
| مواضيع طبية MeSH: | Kidney Calculi*/epidemiology , Kidney Calculi*/pathology , Kidney Calculi*/surgery , Postoperative Cognitive Complications*/epidemiology , Postoperative Cognitive Complications*/pathology, Kidney Pelvis/*pathology , Nephrolithotomy, Percutaneous/*adverse effects, Adult ; Atrophy ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Risk Factors |
| مستخلص: | BACKGROUND This study explored the risk factors for renal atrophy after percutaneous nephrolithotomy (PCNL), and provides a reference for clinical prevention of renal atrophy after PCNL. MATERIAL AND METHODS According to the inclusion and exclusion criteria, the clinical data of 816 patients who underwent PCNL in our hospital from May 2013 to February 2018 were retrospectively collected. Depending on whether the patient had kidney atrophy, they were divided into a renal atrophy group and a non-renal atrophy group. We collected and analyzed data on patient sex, age, kidney location, duration of disease, stone size, hydronephrosis, renal calculus position (renal ureteral junction or multiple pyelonephritis-associated stones), operation time, intraoperative blood loss, perfusion pressure, and pyonephrosis. The indicators with statistically significant differences were selected and multivariate logistic regression analysis was carried out to determine the risk factors for renal atrophy. RESULTS Among 816 patients, 49 had renal atrophy and the incidence rate was 6.01%. Univariate analysis and multivariate logistic regression analysis showed that independent risk factors for renal atrophy after PCNL were: duration of the disease longer than 12 months (OR=4.216, P=0.003, 95% CI: 1.714, 7.354), perfusion pressure >30 mmHg (OR=3.895, P=0.001, 95% CI: 1.685, 8.912), moderate and severe hydronephrosis (OR=5.122, P<0.001, 95% CI: 1.847, 9.863), stones located at the junction of the renal pelvis (OR=3.787, P=0.001, 95% CI: 1.462, 7.654), stones located in multiple calyces (OR=4.531, P=0.014, 95% CI: 1.764, 8.196), and pyonephrosis (OR=10.143, P<0.001, 95% CI: 2.214, 16.248). CONCLUSIONS The main risk factors for renal atrophy after PCNL are: course of disease more than 12 months, moderate and severe hydronephrosis, pyonephrosis, multiple calyceal stones, stones at the junction of the renal pelvis, and intraoperative high perfusion pressure. |
| References: | Urolithiasis. 2017 Feb;45(1):3-9. (PMID: 27915396) Nat Rev Urol. 2014 Jun;11(6):333-41. (PMID: 24818849) Eur Urol. 2016 Aug;70(2):382-96. (PMID: 26876328) Med Sci Monit. 2018 Feb 09;24:818-826. (PMID: 29422481) Clin Immunol. 2014 Jan;150(1):78-87. (PMID: 24333535) World J Urol. 2017 Sep;35(9):1361-1368. (PMID: 28124111) Can J Urol. 1999 Oct;6(5):872-875. (PMID: 11180786) World J Urol. 2017 Dec;35(12):1967-1975. (PMID: 28875295) Urol Int. 2016;97(1):61-6. (PMID: 26784697) Radiat Oncol. 2016 May 26;11:72. (PMID: 27229710) Acad Emerg Med. 2018 Oct;25(10):1129-1137. (PMID: 29663580) J Endourol. 2015 Feb;29(2):153-7. (PMID: 25093997) Eur Urol. 2016 Mar;69(3):475-82. (PMID: 26344917) BJU Int. 2015 Aug;116(2):184-9. (PMID: 25684222) Med Sci Monit. 2016 Nov 14;22:4363-4368. (PMID: 27842051) Iran J Kidney Dis. 2017 May;11(3):180-191. (PMID: 28575878) Surg Laparosc Endosc Percutan Tech. 2007 Aug;17(4):307-10. (PMID: 17710055) Sci Rep. 2017 Jan 31;7:41630. (PMID: 28139722) Nat Rev Dis Primers. 2016 Feb 25;2:16008. (PMID: 27188687) Am Fam Physician. 2011 Dec 1;84(11):1234-42. (PMID: 22150656) Urolithiasis. 2018 Feb;46(1):87-97. (PMID: 29149365) J Urol. 2017 Oct;198(4):858-863. (PMID: 28365271) |
| تواريخ الأحداث: | Date Created: 20200928 Date Completed: 20210520 Latest Revision: 20210520 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC7531202 |
| DOI: | 10.12659/MSM.919970 |
| PMID: | 32986688 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1643-3750 |
|---|---|
| DOI: | 10.12659/MSM.919970 |